Key Points 1. Hepatic epithelioid hemangioendothelioma is a rare disease with a variable natural history; current data support liver transplantation for unresectable disease. 2. Anti-vascular endothelial cell growth factor therapy may change the approach to hepatic epithelioid hemangioendothelioma in the future. 3. The role of liver transplantation in the treatment of neuroendocrine tumors remains unclear; more data obtained by standardized approaches are needed for evidence-based decision making. 4. Liver transplantation is curative in highly selected patients with perihilar cholangiocarcinoma when it is combined with neoadjuvant therapy. Liver Transpl 16:S22-S25, 2010. copy; 2009 AASLD.
ASJC Scopus subject areas